Navigation Links
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Date:12/17/2009

es and other governmental regulatory bodies, including the FDA's review of any filings we make in connection with the treatment protocol; delays in the FDA's or other health regulatory authorities' approval of any applications we file or refusals to approve such filings; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application we file for any such drug product; the identification of lead compounds; the risk that we may fail to satisfy certain conditions relating to grants we have received from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade which may lead to our being required to refund grants previously received together with interest and penalties; the risk that the Office of the Chief Scientist may not deliver to us all of the funds awarded to us; uncertainties related to the ability to attract and retain partners for our technologies and products under development; and other factors described in our filings with the Securities and Exchange Commission. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings for such clinical trials. Further, even if favorable testing data is generated by clinical trials of drug products, the FDA may not accept or approve an NDA filed by a pharmaceutical or biotechnology company for such drug product. Failure to obtain FDA approval of any of our drug candidates in a timely manner, if at all, will severely undermine our business and results of operation by reducing our potential marketable products and our ability to generate corresponding product revenues. Under our approved treatment protocol, taliglucerase alfa might be provided only to a limited number of patients and only for a limited time. The FDA's approval of the treatment protocol or the fast track design
'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
2. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
3. CVS Caremark Names New Chief Human Resources Officer
4. Cardinal Health Names Carrie Cox to Board of Directors
5. Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO
6. The Deal Names Abbott Top Dealmaker for Second Consecutive Year
7. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
8. AMD LASERS Names Dr. James Jesse as Medical Director
9. Arcadia Resources Names Stephen Goldsmith to Board of Directors
10. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
11. Codexis Names Fernando Valle Research Fellow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Vaccinogen, Inc. (OTC.QB: VGEN), a ... of Directors has unanimously elected Co-founder, President, Chief Executive ... to the role of Chairman of the Board. Mr. ... who resigned from the Board and his role as ... role to pursue his candidacy for the President of ...
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... of the "Will Theranos Turn the Lab Industry ... Theranos has received much praise along with a healthy ... "gone public" with their potentially disruptive laboratory solution. Behind ... Has Theranos scaled microfluidic technology across a ...
Breaking Medicine Technology:Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 2Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 3Will Theranos Turn the Lab Industry Upside Down? 2
... Mass. , June 1 SynapDx Corp., a new company ... autism, announced the completion of a $9 million Series A ... Partners. , , , ... profound effect on children and their families," said Stanley N. Lapidus ...
... FRANCISCO , June 1 Prostate cancer ... FIRMAGON® (degarelix for injection) after one year of treatment ... of a Phase III extension study(1) presented here at ... used in monitoring prostate cancer patients, treatment response, and ...
Cached Medicine Technology:Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 2Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 3Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 4Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year 5
(Date:5/5/2015)... 2015 In the upbeat Moms Helping Moms ... moms to support each other. Parenting is a tough ... makes it so much easier. Mothers talk about how ... less alone and help them realize there’s no perfect parent; ... who are clearly dear friends share that it's just that, ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Specialty ... collaborating with American Eagle Outfitters on a collection ... natural beauty. , For the debut five-piece ... Aerie by American Eagle ; the retailer's ... body-image campaign, called "Aerie REAL," uses models of ...
(Date:5/5/2015)... 05, 2015 Igantia , an ... leads an international initiative to examine key biological milestones ... human lifespan. Scientists at Igantia believe that better ... the initiation of her menstrual cycle to her transition ... aging and, ultimately, extend the lifespan. , By ...
(Date:5/5/2015)... 05, 2015 Care Logistics ... called “Medicare Breakeven Challenges? A Model to ... ,     Formulas for two critical ... but should be ,     A model ... space” and ensures sustained efficient operations , ...
(Date:5/5/2015)... 05, 2015 Every year, news articles appear ... out, the worst dry eye season is spring, also known ... most of the United States. The only season offering a ... Sharon Kleyne, host of the Sharon Kleyne Hour™ Power of ... radio show of May 11, 2015. Kleyne is the inventor ...
Breaking Medicine News(10 mins):Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Care Logistics Publishes a New Hospital Guidebook for Achieving Medicare Breakeven 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Unfortunately for us, there is no formula for fulfillment or ... religion and science time and again for answers to our ... Confucius and Plato, and science continues to piece together some ... Psychologists Nansook Park and Christopher Peterson from the University ...
... at Massachusetts General Hospital (MGH) has been awarded $15 ... Diseases to investigate how the hepatitis C virus (HCV) ... The five-year grant will support a Cooperative Center for ... on how some individuals successfully recover from HCV while ...
... network of medical research institutions across the United States ... to gather critical data about influenza vaccines, including two ... the direction of the National Institute of Allergy and ... Health. "With the emergence of the 2009 ...
... ROSEMONT, Ill., July 22 The American Academy of Orthopaedic ... the treatment of pediatric diaphyseal femur fractures . ... (the bone in the thigh) is a very common childhood injury. ... treatment options for femur fracture, a thighbone injury occurring in an ...
... , WASHINGTON, July 22 ... Medical Doctors Alfred Bonati, M.D., participated yesterday in ... Committee Chairman Michael Steele. Dr. Bonati and other attendees from ... impact of health-care reform on physicians, small businesses, employees and ...
... PHILADELPHIA, July 22 New research from The Children,s ... in acting as gatekeepers for infectious viruses. By using mice genetically ... the study team prevented infection by a common virus that causes ... "This finding is a step to understanding how cell receptors ...
Cached Medicine News:Health News:Life lessons: Where psychology stands on living well 2Health News:Mass. General-based research center will investigate why immune system fails to control hepatitis C 2Health News:NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates 2Health News:NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates 3Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 2Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 3Health News:American Academy of Orthopaedic Surgeons Approves New Guideline for the Treatment of Pediatric Diaphyseal Femur Fractures 4Health News:Internationally Renowned Surgeon Reaches out to RNC, Hispanic Community 2Health News:Eliminating Cell Receptor Prevents Infections in Animal Study 2Health News:Eliminating Cell Receptor Prevents Infections in Animal Study 3
Narrow smooth jaws. Serrated handle with polished finish....
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
Round solid 15 mm wide lower plate. Open upper plate with inside diameter 12 mm. Serrated handle with locking thumb screw and polished finish....
Oval solid 17 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: